For the 34 prioritisation (January 2018), 15 drugs were filtered out of 405 identified and were sent to prioritisation. Of these, seven drugs were ranked as "highly relevant" by the expert panel, seven as "relevant" and one as "not relevant". For "highly relevant" drugs, further information including, for example, abstracts of phase III studies and licensing status is contained in this document.